Jane Street
MRSN

Jane Street’s Mersana Therapeutics MRSN Stock Holding History

Jane Street’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,328
Closed -$548K – 10179
2024
Q4 		$548K Hold
15,328
– – ﹤0.01% 6595
2024
Q3 		$724K Hold
15,328
– – ﹤0.01% 6544
2024
Q2 		$770K Sell
15,328
-8
-0.1% -$578 ﹤0.01% 6279
2024
Q1 		$1.72M Buy
15,336
+8
+0.1% +$795 ﹤0.01% 4400
2023
Q4 		$889K Buy
+15,328
New +$617K ﹤0.01% 5759
2023
Q3 		– Sell
-660
Closed -$54.3K – 9107
2023
Q2 		$54.3K Buy
+660
New +$96.6K ﹤0.01% 8191
2022
Q2 		– Sell
-1,268
Closed -$126K – 10431
2022
Q1 		$126K Sell
1,268
-888
-41% -$104K ﹤0.01% 9337
2021
Q4 		$335K Buy
2,156
+68
+3% +$13.2K ﹤0.01% 7968
2021
Q3 		$492K Buy
+2,088
New +$610K ﹤0.01% 7302

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $135M AUM 36.32% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street's MRSN Position: Q3 2025 in Review

Jane Street sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 20,447 shares — an estimated $151K sold.

Jane Street first reported a position in MRSN in Q1 2019 and held it in 20 quarters. The position peaked at $2.22M in Q4 2020. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • Jane Street reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jane Street sold 20,447 Mersana Therapeutics shares in Q3 2025, an estimated $151K.
  • Jane Street first reported a position in Mersana Therapeutics in Q1 2019 and held it in 20 quarters.
  • Jane Street's Mersana Therapeutics position peaked at $2.22M in Q4 2020.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on Jane Street's 13F filing for Q3 2025, filed 14 Nov 2025.